Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial

The American Journal of Medicine
A J GarberJ L Rohlf

Abstract

To study the efficacy and safety of various dosages of metformin as compared with placebo in patients with type II diabetes mellitus. A 14-week, multicenter, double-blind, dose-response study was conducted. After a 3-week, single-blind, placebo-controlled washout, 451 patients with fasting plasma glucose levels of at least 180 mg/dL were randomized to receive an 11-week course of placebo or metformin given at 500, 1000, 1500, 2000, or 2500 mg daily. Metformin improved glucose variables as compared with placebo. The adjusted mean changes in fasting plasma glucose from baseline associated with each metformin group at week 7, 11, or at endpoint exceeded those associated with placebo by 19 to 84 mg/dL at dosages of 500 to 2000 mg daily, respectively. The corresponding between-group differences in glycated hemoglobin (HbA1c) ranged from 0.6% to 2.0% at dosages of 500 to 2000 mg daily, respectively. All between-group differences were significant (P < 0.05) for both fasting plasma glucose and HbA1c at week 7, week 11, and endpoint, except for the difference between placebo and metformin 500 mg in fasting plasma glucose at endpoint (P = 0.054). Treatment-related adverse events occurred in 15% of patients in the placebo group and in 28%...Continue Reading

Citations

Dec 31, 2002·The Annals of Pharmacotherapy·Jamshed K KhanThomas R Hornick
Nov 19, 2003·Current Opinion in Obstetrics & Gynecology·Tasoula Tsilchorozidou, Gordana M Prelevic
Dec 14, 2004·Southern Medical Journal·Lisa L Willett, Eric S Albright
Apr 4, 2008·Pharmacogenomics·Hiroshi TakaneIchiro Ieiri
Aug 30, 2008·Expert Opinion on Drug Metabolism & Toxicology·Sherwin L SchwartzVerne E Cowles
Sep 9, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·John H B Scarpello, Harry C S Howlett
Jun 12, 2010·Diabetic Medicine : a Journal of the British Diabetic Association·J TomlinsonJ Pinkney
Dec 17, 2009·British Journal of Clinical Pharmacology·Matthew P DoogueMei Zhang
Feb 5, 2011·Postgraduate Medicine·Serge Jabbour, Barry Ziring
May 15, 2013·American Journal of Therapeutics·Sanjay Chatterjee, Saurav Chatterjee
Jan 6, 2012·Wiener klinische Wochenschrift·Bernhard Ludvik, Guntram Schernthaner
Oct 28, 2014·Expert Opinion on Pharmacotherapy·Serge Jabbour
Nov 13, 2014·Diabetes Technology & Therapeutics·Yuxin HuangWen Tan
Dec 17, 2014·The Medical Journal of Australia·Jenny E GuntonUNKNOWN Australian Diabetes Society
Apr 30, 2016·Basic & Clinical Pharmacology & Toxicology·Tore Bjerregaard StageAnton Pottegård
Dec 18, 2016·Diabetes, Obesity & Metabolism·Fabrice Bonnet, André Scheen
Sep 7, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·A HolsteinE H Egberts
Aug 24, 1999·Endocrine Reviews·L PoretskyL C Giudice
Aug 6, 2000·The Annals of Pharmacotherapy·M S Rendell, W R Kirchain
Dec 14, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Jaime A DavidsonHarry C S Howlett
Jul 15, 2004·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·S Mudaliar, R R Henry
Aug 18, 2006·Current Medical Research and Opinion·Bart Staels
Sep 19, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·M W StewartA Hamann
Dec 26, 2007·Current Medical Research and Opinion·S M BeardR A Malik
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Dawn Smiley, Guillermo Umpierrez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.